SUMMARY In order to find the optimal dosage schedule of phenobarbitone for neonatal convulsions, four groups of patients were studied. Twelve infants (group 1) received a mean phenobarbitone dose of 9 5 mg/kg a day given intramuscularly for 3 days followed by 5-8 mg/kg a day given intramuscularly and then orally. Six infants (group 2) received a mean intravenous loading dose of 9 5 mg/kg followed by 6 8 mg/kg a day given intramuscularly or orally. Nine infants (group 3) received a mean loading dose of 14-9 mg/kg intravenously followed by a maintenance dose of 5 9 mg/kg a day. Thirteen patients (group 4) received a mean intramuscular loading dose of 15 2 mg/kg followed by 5 9 mg/kg a day. Blood samples were taken regularly and phenobarbitone levels were determined by gas liquid chromatography. A mean intravenous or intramuscular loading dose of 15 mg/kg of phenobarbitone safely achieved therapeutic levels within 2 hours of injection and high therapeutic levels were maintained with a dose of 6 mg/kg a day. Group 2. Six infants aged between 1 and 25 (mean 10-2) days and weighing between 1650 and 3580 (mean 3053) g received a mean loading dose of 9-5 mg/kg intravenously followed by a mean maintenance dose of 6-8 mg/kg a day given intramuscularly for at least the first 6 doses and then orally or intramuscularly. The first maintenance dose was given 12 hours after the end of the infusion. The aetiology of the seizures was: birth hypoxia 2; hydrocephalus and congenital heart disease 1; prematurity and intracranial haemorrhage 1; recurrent hypoxia due to tracheo-oesophageal fistula 1; idiopathic 1*.
Patients and methods
The patients were divided into four groups receiving varying dosage regimens as follows: Group 1. Twelve infants aged between 1 and 5 (mean 3-5) days whose birthweights were between 2000 and 3905 (mean 3145) g received a mean dose of 9-5 mg/kg a day given intramuscularly in two divided doses for 3 days. The dose was then reduced to a mean of 5.8 mg/kg a day given intramuscularly or orally. The aetiology of the seizures was: birth hypoxia 2; subarachnoid haemorrhage 1: Poland syndrome 1; ventricular septal defect and cerebral embolism 1; idiopathic 7*. Group 2. Six infants aged between 1 and 25 (mean 10-2) days and weighing between 1650 and 3580 (mean 3053) g received a mean loading dose of 9-5 mg/kg intravenously followed by a mean maintenance dose of 6-8 mg/kg a day given intramuscularly for at least the first 6 doses and then orally or intramuscularly. The first maintenance dose was given 12 hours after the end of the infusion. The aetiology of the seizures was: birth hypoxia 2; hydrocephalus and congenital heart disease 1; prematurity and intracranial haemorrhage 1; recurrent hypoxia due to tracheo-oesophageal fistula 1; idiopathic 1*. 5 ,ug/ml (20 In group 1, infants achieved a mean plasma level at 24 hours of 7 5 ,ug/ml (30 ,umol/l) with a range of 5.5 to 11 .5 tg/ml (22 to 46 ,umol/l). At 72 hours, the mean level was 21 ptg/ml (84 ,umol/l) and the range 13.5 to 28 tg/ml (54 to 112 timol/l). By the end of the first week values were similar and declined slowly thereafter. Thus all infants had achieved levels above 10 ,ug/ml (40 tmol/l) by 72 hours but only one had risen above this level by 24 hours.
In group 2, the mean intravenous infusion of 9.5 mg/kg produced a mean plasma level of 9 ,ug/ml (36 ,mol/l). There was no significant decline in None of the patients in the controlled group had a blood level below 16-9 ,ug/ml (67.6 ,umol/l) whereas those with uncontrolled seizures had levels well above and below this level. Since there were more than twice as many uncontrolled patients as controlled, their series was clearly weighted by the inclusion of an unusual number of refractory cases. In our experience some patients have been controlled at plasma levels between 7 and 15,g/ml (28 and 60 ,umol/l). Jalling6 reported similar results to our own. Further study is needed to define the lower level of the therapeutic range in the neonate.
In the absence of firmer data, we elected at the start of these studies in 1975 to regard a range of 10-25 tg/ml (40-100 ,mol/l) as likely to be effective and non-toxic for the convulsing neonate and attempted to design dosage schedules that would result in the rapid achievement and maintenance of such levels with reliability.
In a preliminary study of 6 infants given the often recommended dosage of 6 mg/kg a day, we showed that only one infant achieved therapeutic levels by 72 hours. We therefore studied varying but higher dosage levels in groups 1 to 4 of the current series.
Although group 1 patients had all achieved therapeutic serum levels by 72 hours, most of them had subtherapeutic levels at 24 hours. Once achieved, serum levels were well maintained on the maintenance dose. In group 2, a mean intravenous loading dose of 9-5 mg/kg achieved serum levels close to the lower end of the therapeutic range. The mean loading dose of 15 mg/kg given either intravenously as in group 3 or intramuscularly as in group 4 achieved excellent therapeutic levels, almost immediately in group 3, and within 4 hours in group 4 (confirming the work of Jalling6). The levels were well maintained on the maintenance dosage of about 6 mg/kg a day for the duration of the study. Because of the occasional finding of unexpectedly high levels we recommend that a serum level should be taken on days 3 and 7 to estimate progress.
In line with the observations of Volpe2 no serious side effects occurred. Many babies appeared lethargic and heavily sedated but it was often difficult to separate the effects of the anticonvulsant from those of the underlying disorder. One infant who had suffered hypoxic seizures secondary to inhalation of gastric contents secondary to an H-type tracheooesophageal fistula had a further episode of inhalation within a few hours of an intravenous loading dose of phenobarbitone. He suffered no serious sequelae and made a complete recovery after corrective surgery. No infant required artificial respiration as a result of phenobarbitone administration, although several were on respirators before institution of treatment with phenobarbitone. Because of the impossibility of separating the serious sequelae of the underlying condition from those of the phenobarbitone administration per se, it is difficult to evaluate the long-term effects of the drug itself on cerebral function and maternal-infant bonding.
Against Phenobarbitone dosage in neonatal convulsions 657 to suggest the duration of treatment on the basis of the present study.
The currently recommended regimen appears to have advantages over that of Painter et al.7 in that the frequent very high and possibly toxic serum levels achieved in that study were rarely seen by us. We disagree with Jalling6 that it is difficult to con--truct rational maintenance dose schedules but agree that optimal dosage must be monitored by serum level estimations. Our results confirm that the rapid achievement of therapeutic levels results in earlier control of serial seizures in the newborn as shown by the shorter mean time to achieve seizure control in the groups given intravenous and high intramuscular loading doses. The possibility that the higher pulse levels created by the intravenous loading route may have advantages over the intramuscular route is currently being investigated in our unit.
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